The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

Author： Pincelli Carlo  

Publisher： Springer Publishing Company

ISSN： 0340-3696

Source： Archives of Dermatological Research, Vol.298, Iss.7, 2006-12, pp. : 329-338

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Efficacy of Efalizumab in Patients With Chronic Plaque Psoriasis: Results From Three Randomized Placebo-Controlled Phase III Trials: Part I

By Pariser David   Gordon Kenneth   Papp Kim   Leonardi Craig   Kwon Paul   Compton Peter   Rundle Amy   Walicke Patricia   Lebwohl Mark  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 6, 2005-12 ,pp. : 303-312

Springer Publishing Company

Access to resources Recommend Favorite

Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II

By Papp Kim   Camisa Charles   Stone Stephen   Caro Ivor   Wang Xiaolin   Compton Peter   Walicke Patricia   Gottlieb Alice  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 6, 2005-12 ,pp. : 313-323

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of Recalcitrant Dermatomyositis with Efalizumab

By Huber Andrea   Gaffal Evelyn   Bieber Thomas   Tüting Thomas   Wenzel Joerg  

Acta Dermato-Venereologica, Vol. 86, Iss. 3, 2006-05 ,pp. : 254-255

Medical Journals Limited

Access to resources Recommend Favorite

Efalizumab-associated papular psoriasis: An adverse reaction to efalizumab in three cases

By Antonucci Angela   Bardazzi Federico   Balestri Riccardo   Patrizi Annalisa  

Journal of Dermatological Treatment, Vol. 20, Iss. 1, 2009-01 ,pp. : 61-62

Informa Healthcare

Access to resources Recommend Favorite

Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment

By Kop Else   Korver John   Van Ruysevelt Delphine   De Jong Elke   Van der Valk Pieter   Van de Kerkhof Peter  

Journal of Dermatological Treatment, Vol. 20, Iss. 1, 2009-01 ,pp. : 67-69

Informa Healthcare

Access to resources Recommend Favorite